Alaskan SWF Invests in Series B on Anti-Cancer Biotech
Posted on 01/27/2016
The Alaska Permanent Fund Corporation (APFC) participated in a US$ 61 million Series B round to invest in Cambridge, Massachusetts-based Codiak BioSciences Inc., a company focused on the advanced research and clinical development of exosomes, which are tiny membrane sacs, or vesicles, that are released by both healthy and cancerous cells, for therapeutic and diagnostic […]
- Alaska Permanent Fund Corporation
- Alternatives
- ARCH Venture Partners
- Biotech
- Codiak BioSciences
- Flagship Ventures
- pharmaceuticals
- Venture Capital
